1. Home
  2. GILD vs ELV Comparison

GILD vs ELV Comparison

Compare GILD & ELV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GILD
  • ELV
  • Stock Information
  • Founded
  • GILD 1987
  • ELV 1944
  • Country
  • GILD United States
  • ELV United States
  • Employees
  • GILD N/A
  • ELV N/A
  • Industry
  • GILD Biotechnology: Biological Products (No Diagnostic Substances)
  • ELV Medical Specialities
  • Sector
  • GILD Health Care
  • ELV Health Care
  • Exchange
  • GILD Nasdaq
  • ELV Nasdaq
  • Market Cap
  • GILD 110.9B
  • ELV 92.9B
  • IPO Year
  • GILD 1992
  • ELV N/A
  • Fundamental
  • Price
  • GILD $88.46
  • ELV $400.83
  • Analyst Decision
  • GILD Buy
  • ELV Strong Buy
  • Analyst Count
  • GILD 24
  • ELV 14
  • Target Price
  • GILD $93.91
  • ELV $543.07
  • AVG Volume (30 Days)
  • GILD 7.3M
  • ELV 2.0M
  • Earning Date
  • GILD 11-06-2024
  • ELV 10-17-2024
  • Dividend Yield
  • GILD 3.48%
  • ELV 1.63%
  • EPS Growth
  • GILD N/A
  • ELV 9.17
  • EPS
  • GILD 0.10
  • ELV 27.42
  • Revenue
  • GILD $28,299,000,000.00
  • ELV $174,015,000,000.00
  • Revenue This Year
  • GILD $5.71
  • ELV N/A
  • Revenue Next Year
  • GILD $0.37
  • ELV $7.68
  • P/E Ratio
  • GILD $911.55
  • ELV $14.62
  • Revenue Growth
  • GILD 3.31
  • ELV 3.20
  • 52 Week Low
  • GILD $62.07
  • ELV $397.92
  • 52 Week High
  • GILD $98.90
  • ELV $567.26
  • Technical
  • Relative Strength Index (RSI)
  • GILD 46.13
  • ELV 28.96
  • Support Level
  • GILD $89.01
  • ELV $421.61
  • Resistance Level
  • GILD $98.90
  • ELV $433.38
  • Average True Range (ATR)
  • GILD 2.11
  • ELV 9.26
  • MACD
  • GILD -0.63
  • ELV 1.70
  • Stochastic Oscillator
  • GILD 8.58
  • ELV 8.21

About GILD Gilead Sciences Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

About ELV Elevance Health Inc.

Elevance Health remains one of the leading health insurers in the U.S., providing medical benefits to 47 million medical members as of December 2023. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states through government-sponsored programs such as Medicaid and Medicare Advantage plans, too.

Share on Social Networks: